CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India
about
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allCurrent trends and intricacies in the management of HIV-associated pulmonary tuberculosisPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsTherapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapyEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionEffects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsHaplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPlasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE studyEffect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.Individualization of antiretroviral therapy.Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisManagement of individuals requiring antiretroviral therapy and TB treatment.Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patientsManagement of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.TB-HIV co-infection: a catastrophic comradeship.Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.Practical Pharmacology of Methadone: A Long-acting Opioid.Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q24606937-F5DE40C7-0989-4122-BA56-3DB7B94C9AF7Q24609011-B28B314D-B3D4-4379-BBB8-1DD61B48A803Q28069032-9783FC7F-6633-490F-B9D2-AE9F1A1EA750Q28478275-4692CFD1-4EBA-44B4-BBE6-FFA47D4A2565Q28539806-3A4536C5-2568-409E-B33A-4CAAD0206E6FQ28548638-D9E82F38-20D3-4843-B93C-91D92AABD07AQ33809438-8871754C-1539-4545-BC54-F2305540DD19Q34060396-1F593AEA-87C1-492D-A713-860192455C09Q34756398-8A932953-2A57-4AA0-A32C-32666868FF26Q35065867-1E9EBB13-0833-4610-9DF6-9B851329D155Q35114865-1EAA3450-FD7E-40FF-8CAB-F2322FD12670Q35132410-207ECFC8-F67C-419F-8BA7-60552E9821F2Q35974648-B9CA5A2D-7861-47B0-B0BF-A61D10495239Q36171561-6A0ED24D-AB87-4204-BCBD-5DE99A7A2267Q36343668-0AF39126-5E97-4E90-832B-A72589290D9EQ36441423-974B5CC7-03AC-4C3A-BDDD-5450AF982EDEQ36558327-ED5B4D35-AE88-46F6-8030-E01178B5A507Q37036991-4E474B37-77B4-4266-BAF8-4DBD570CD1C8Q37052162-972A1400-6499-42E4-A103-0F59E7A7A2E0Q37392789-ADF8F887-1691-40B2-ADF3-0C7225D66FE5Q37466856-A191EC28-D86A-492E-8C27-92295067665CQ37666456-5D36EB61-A47C-4210-8E86-05333878182FQ37690861-E50E7C36-03CE-4DB8-8F70-34D5592E0C4FQ38107500-7234B0A9-BEA4-428C-8C6E-A3CB176D8DB4Q38207924-F68E4680-30EA-4367-BE86-E7E19F11B5CDQ38855121-8B982E9B-F0FB-4B35-B3BD-924F7AE4B237Q38861140-09E40D0F-4918-40BA-BC2D-2CC64BAEA396Q39039468-34CADA77-0A3F-4B6D-851A-109CB1A09673Q39826708-95C3DB81-FF6C-4C76-94DC-A97C37BD79E7Q40207726-A34B6F05-7F11-4ABC-8922-4C6FF5B67978Q40577108-2B3BC251-440E-4773-AA95-7ADCE6FDC2F4Q40694902-205F6E40-D251-4709-B1C0-A4C8F11060A8Q43217465-A27656E2-C6A7-407A-84D3-89B106F874E3Q47102399-68A9A24D-7220-40CA-B0B3-3DFB39EB0E9DQ55032616-9066BD82-C371-48BA-B8B3-E811CB0A2104Q58612379-6C425D6D-35A4-4FC0-B493-2CB79D3C0B3F
P2860
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP2B6 G516T polymorphism but ...... fected patients in South India
@en
CYP2B6 G516T polymorphism but ...... ected patients in South India.
@nl
type
label
CYP2B6 G516T polymorphism but ...... fected patients in South India
@en
CYP2B6 G516T polymorphism but ...... ected patients in South India.
@nl
prefLabel
CYP2B6 G516T polymorphism but ...... fected patients in South India
@en
CYP2B6 G516T polymorphism but ...... ected patients in South India.
@nl
P2093
P2860
P356
P1476
CYP2B6 G516T polymorphism but ...... fected patients in South India
@en
P2093
A K Hemanth Kumar
G Narendran
Geetha Ramachandran
Pradeep Menon
Sikhamani Rajasekaran
P2860
P304
P356
10.1128/AAC.00899-08
P407
P577
2009-01-05T00:00:00Z